Germany donates 10,000 doses of Casirivimab/Imdevimab to Uzbekistan

The drugs arrived in Tashkent on September 2.

Reportedly, officials of the Ministry of Health, staff of the German Embassy and journalists were present at the time of receiving the monoclonal antibodies at the Tashkent airport.

Casirivimab/Imdevimab, sold under the brand name REGEN-COV among others, is a medicine developed by the American biotechnology company Regeneron Pharmaceuticals. It is an artificial "antibody cocktail" designed to produce resistance against the SARS-CoV-2 coronavirus responsible for the COVID-19 pandemic.

Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses. Casirivimab and Imdevimab are monoclonal antibodies that are specifically directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells.